Plant-based pipeline Jaguar Health focuses on novel, plant-based, non-opioid prescription medicines targeting GI distress in humans and animals, with subsidiaries like Napo Pharmaceuticals and Magdalena Biosciences. Sales opportunities exist in expanding crofelemer access in Europe through Napo Therapeutics and leveraging plant-derived CNS/mental health candidates via Magdalena for targeted therapeutic areas.

Europe expansion Jaguar is the majority shareholder of Napo Therapeutics S.p.A. and aims to expand crofelemer access in Europe, signaling a clear market entry and collaboration potential with European distributors, healthcare providers, and regulatory bodies for GI and related indications.

Animal health growth Recent product line expansions include Neonorm Dog and ongoing Pet health initiatives, presenting cross-sell opportunities to veterinary clinics and pet specialty channels, particularly for GI-related conditions and adjunctive therapies in companion animals.

Strategic partnerships Joint venture with Filament Health to form Magdalena Biosciences highlights a focus on natural plant-based CNS solutions. This creates opportunities to partner on co-development, licensing, or co-marketing of mental health and ADHD-focused products for adults.

Investor-backed momentum With reported revenue and a funding base of capital raised, Jaguar demonstrates a viable platform for partnering with specialty pharma distributors, contract manufacturers, and research organizations to accelerate clinical programs, expand manufacturing capacity, and enter new markets.